Clinical trial
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
NCT02754141 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 21, 2016
- Completion date
- October 12, 2021
- Enrollment
- 235 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.
malignant solid tumor